• Twitter
  • Jobs
ProCURE oncology
  • HOME
  • ABOUT US
  • RESEARCH GROUP
    • Molleví’s Lab
    • Antolin’s Lab
    • Alemany’s & Piulats’s lab
    • Martínez-Balibrea’s Lab
    • Aytes’s Lab
    • Belver’s Lab
    • Pujana’s Lab
    • Menendez’s Lab
    • Sureda’s & Farre’s Lab
    • Casanovas’s Lab
    • Viñals’s lab
  • INNOVATION
  • NEWS
  • CONTACT
  • Menu Menu

News

Identification of differential biological activity and synergy between the PARP inhibitor rucaparib and its major metabolite

9 de February de 2024
Cell Chem Biol. 2024 Feb 6:S2451-9456(24)00043-6. doi: 10.1016/j.chembiol.2024.01.007.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2024-02-09 11:00:002024-02-09 11:00:00Identification of differential biological activity and synergy between the PARP inhibitor rucaparib and its major metabolite

Identification of differential biological activity and synergy between the PARP inhibitor rucaparib and its major metabolite

9 de February de 2024
Cell Chem Biol. 2024 Feb 6:S2451-9456(24)00043-6. doi: 10.1016/j.chembiol.2024.01.007.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2024-02-09 11:00:002024-02-09 11:00:00Identification of differential biological activity and synergy between the PARP inhibitor rucaparib and its major metabolite

Biological basis of extensive pleiotropy between blood traits and cancer risk

3 de February de 2024
Genome Med. 2024 Feb 2;16(1):21. doi: 10.1186/s13073-024-01294-8.ABSTRACTBACKGROUND:…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2024-02-03 11:00:002024-02-03 11:00:00Biological basis of extensive pleiotropy between blood traits and cancer risk

Axicabtagene ciloleucel versus tisagenlecleucel for relapsed or refractory large B-cell lymphoma: a systematic review and meta-analysis

28 de January de 2024
Transplant Cell Ther. 2024 Jan 26:S2666-6367(24)00171-4. doi:…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2024-01-28 11:00:002024-01-28 11:00:00Axicabtagene ciloleucel versus tisagenlecleucel for relapsed or refractory large B-cell lymphoma: a systematic review and meta-analysis

Impact of SARS-CoV-2 vaccines and recent chemotherapy on COVID-19 morbidity and mortality in patients with soft tissue sarcoma: an analysis from the OnCovid registry

22 de January de 2024
Ther Adv Med Oncol. 2024 Jan 18;16:17588359231225028. doi: 10.1177/17588359231225028.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2024-01-22 11:00:002024-01-22 11:00:00Impact of SARS-CoV-2 vaccines and recent chemotherapy on COVID-19 morbidity and mortality in patients with soft tissue sarcoma: an analysis from the OnCovid registry

NOTCH1-Induced T-Cell Acute Lymphoblastic Leukemia In Vivo Models

18 de January de 2024
Methods Mol Biol. 2024;2773:9-24. doi: 10.1007/978-1-0716-3714-2_2.ABSTRACTT-cell…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2024-01-18 11:00:002024-01-18 11:00:00NOTCH1-Induced T-Cell Acute Lymphoblastic Leukemia In Vivo Models

Unanswered questions following reports of secondary malignancies after CAR-T cell therapy

9 de January de 2024
Nat Med. 2024 Jan 9. doi: 10.1038/s41591-023-02767-w. Online…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2024-01-09 11:00:002024-01-09 11:00:00Unanswered questions following reports of secondary malignancies after CAR-T cell therapy

Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation

6 de January de 2024
Lancet Haematol. 2024 Jan 3:S2352-3026(23)00342-3. doi: 10.1016/S2352-3026(23)00342-3.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2024-01-06 11:00:002024-01-06 11:00:00Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation

Oncolytic adenovirus coding for shedding-resistant MICA enhances immune responses against tumors

5 de January de 2024
Cancer Immunol Immunother. 2024 Jan 5;73(1):5. doi: 10.1007/s00262-023-03611-3.ABSTRACTCancer…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2024-01-05 11:00:002024-01-05 11:00:00Oncolytic adenovirus coding for shedding-resistant MICA enhances immune responses against tumors

The EBMT: History, Present, and Future

1 de January de 2024
2024 Apr 11. In: Sureda A, Corbacioglu S, Greco R, Kröger N,…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2024-01-01 11:00:002024-01-01 11:00:00The EBMT: History, Present, and Future

Classical Hodgkin’s Lymphoma

1 de January de 2024
2024 Apr 11. In: Sureda A, Corbacioglu S, Greco R, Kröger N,…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2024-01-01 11:00:002024-01-01 11:00:00Classical Hodgkin’s Lymphoma

Graft Failure

1 de January de 2024
2024 Apr 11. In: Sureda A, Corbacioglu S, Greco R, Kröger N,…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2024-01-01 11:00:002024-01-01 11:00:00Graft Failure
Page 20 of 87«‹1819202122›»

Filter by categories

  • Alemany’s & Piulats’s lab (133)
  • Antolin's lab (36)
  • Aytes's Lab (25)
  • Belver's Lab (25)
  • Casanovas's Lab (77)
  • Martínez-Balibrea's Lab (43)
  • Menendez's Lab (121)
  • Molleví's Lab (35)
  • Pujana's Lab (110)
  • Sin categoría (5)
  • Sureda's & Farre's Lab (312)
  • Viñals's lab (111)

Twitter

Tweets by ProcureICO
Program Against Cancer Therapeutic Resistance

CONTACT US

Campus IDIBELL
(L’Hospitalet del Llobregat)
Hospital Duran i Reynals, Gran Via 199,
L’Hospitalet del Llobregat,
Barcelona 08908
Tel. +34 93 260 7952

Campus IGTP-IJC
(Badalona)
Campus Can Ruti – IGTP – Building Muntanya,
Rd. Can Ruti, Camí de les escoles s/n,
Badalona, Barcelona 08916
Tel. +34 93 554 3069

Campus IDIBGI
(Girona)
Parc Hospitalari Martí i Julià de Salt, Dr. Castany s/n,
Salt, Girona 17190
Tel. +34 872 987 087

© Copyright - Edisenius
  • Privacy Policy
  • Cookie Policy
  • Legal Notice
Scroll to top
Manage cookie consent
To offer the best experiences, we use technologies such as cookies to store and/or access device information. Consent to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Failure to consent, or withdrawal of consent, may adversely affect certain features and functions.
Functional Always active
Storage or technical access is strictly necessary for the legitimate purpose of allowing the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. Storage or technical access that is used exclusively for anonymous statistical purposes. Without a requirement, voluntary compliance by your Internet service provider, or additional records from a third party, information stored or retrieved solely for this purpose cannot be used to identify you.
Marketing
Storage or technical access is necessary to create user profiles to send advertising, or to track the user on a website or several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
See preferences
{title} {title} {title}